Loomis, Sayles & Company
SCMP

Loomis, Sayles & Company’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Loomis, Sayles & Company’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-378
Closed -$5K – 1156
2016
Q3 		$5K Buy
378
+254
+205% +$2.99K ﹤0.01% 898
2016
Q2 		$1K Hold
124
– – ﹤0.01% 997
2016
Q1 		$1K Hold
124
– – ﹤0.01% 1039
2015
Q4 		$2K Hold
124
– – ﹤0.01% 1005
2015
Q3 		$2K Hold
124
– – ﹤0.01% 999
2015
Q2 		$2K Buy
+124
New +$2.15K ﹤0.01% 900

Other funds holding SCMP

LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return

Loomis, Sayles & Company's SCMP Position: Q4 2016 in Review

Loomis, Sayles & Company sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2016, closing a stake of 378 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in SCMP in Q2 2015 and held it in 6 quarters. The position peaked at $5K in Q3 2016. 165 funds tracked by Wall St. Rank hold SCMP as of Q4 2016.

  • Loomis, Sayles & Company reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 378 Sucampo Pharmaceuticals, Inc. shares in Q4 2016, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2015 and held it in 6 quarters.
  • Loomis, Sayles & Company's Sucampo Pharmaceuticals, Inc. position peaked at $5K in Q3 2016.
  • 165 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2016.

Based on Loomis, Sayles & Company's 13F filing for Q4 2016, filed 14 Feb 2017.